시장보고서
상품코드
1878856

EV 기반 액체 생검 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제공 형태별, 워크플로우별, 기술별, 검체 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Workflow, By Technology, By Sample Type, By End user, By Region and Competition, 2020-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포외소포(EV) 기반 액체 생검 시장은 2024년에 9,112만 달러로 평가되었으며, 2030년까지 CAGR 9.74%로 성장하여 1억 5,914만 달러에 달할 것으로 예측됩니다.

세포외소포(EV) 기반 액체 생검은 혈액, 소변 등 체액 속에 순환하는 엑소좀 등 세포외소포 내에 포함된 질병 특이적 바이오마커를 비침습적으로 분석하는 방법입니다. 이들 소포는 단백질, 핵산, 지질 등의 분자 물질을 운반하며, 유래 세포의 생리적, 병리적 상태에 대한 지식을 제공합니다. 시장 확대는 특히 암을 비롯한 만성질환의 전 세계적 부담 증가와 조기 비침습적 진단 솔루션에 대한 수요 증가로 인해 크게 촉진되고 있습니다. 생체액 내 EV의 고유한 안정성과 풍부함은 다른 순환 바이오마커에 비해 우위를 제공하며, 주요 성장 촉진요인으로 작용하고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 9,112만 달러
시장 규모 : 2030년 1억 5,914만 달러
CAGR : 2025-2030년 9.74%
가장 빠르게 성장하는 부문 키트 및 어세이
최대 시장 북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

자주 묻는 질문

  • 세계의 세포외소포(EV) 기반 액체 생검 시장 규모는 어떻게 되나요?
  • 세포외소포(EV) 기반 액체 생검의 주요 특징은 무엇인가요?
  • 세포외소포(EV) 기반 액체 생검 시장의 주요 성장 촉진요인은 무엇인가요?
  • 세포외소포(EV) 기반 액체 생검 시장에서 가장 빠르게 성장하는 부문은 무엇인가요?
  • 세포외소포(EV) 기반 액체 생검 시장의 최대 시장은 어디인가요?

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 EV 기반 액체 생검 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 제공 형태별(키트·어세이, 서비스, 기기)
    • 워크플로우별(샘플 조제, 시퀀싱, 데이터 분석)
    • 기술별(분리 기술, 분석 기술)
    • 샘플 유형별(혈액, 소변, 타액, 기타)
    • 최종사용자별(학술연구기관, 제약·바이오테크놀러지 기업, 임상 검사실)
    • 지역별
    • 기업별(2024)
  • 시장 맵

제6장 북미의 EV 기반 액체 생검 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 EV 기반 액체 생검 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 EV 기반 액체 생검 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 중동 및 아프리카의 EV 기반 액체 생검 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 사우디아라비아
    • 아랍에미리트
    • 남아프리카공화국

제10장 남미의 EV 기반 액체 생검 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 브라질
    • 콜롬비아
    • 아르헨티나

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 인수합병
  • 제품 출시
  • 최근 동향

제13장 세계의 EV 기반 액체 생검 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

  • 업계내 경쟁
  • 신규 참여의 가능성
  • 공급업체의 능력
  • 고객의 능력
  • 대체품의 위협

제15장 경쟁 구도

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc.(PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM 25.12.15

The Global EV-Based Liquid Biopsy Market , valued at USD 91.12 Million in 2024, is projected to experience a CAGR of 9.74% to reach USD 159.14 Million by 2030. Extracellular vesicle (EV)-based liquid biopsy involves the non-invasive analysis of disease-specific biomarkers encapsulated within extracellular vesicles, such as exosomes, circulating in bodily fluids like blood or urine. These vesicles carry molecular cargoes including proteins, nucleic acids, and lipids, providing insights into the physiological and pathological state of originating cells. The market's expansion is significantly driven by the increasing global burden of chronic diseases, particularly cancer, and the rising demand for early, non-invasive diagnostic solutions. The inherent stability and abundance of EVs in biofluids, offering advantages over other circulating biomarkers, also act as key growth facilitators.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 91.12 Million
Market Size 2030USD 159.14 Million
CAGR 2025-20309.74%
Fastest Growing SegmentKits & Assays
Largest MarketNorth America

Key Market Drivers

The escalating global cancer burden fundamentally drives the EV-based liquid biopsy market. Traditional diagnostic methods often face limitations in early detection and continuous monitoring, areas where the non-invasive nature of EV liquid biopsies offers significant advantages. As cancer incidence continues its upward trajectory, the urgency for advanced, accessible diagnostic tools intensifies. According to the International Agency for Research on Cancer (IARC), in 2022, there were close to 20 million new cases of cancer worldwide. This pervasive health crisis necessitates innovative solutions that can accurately identify malignancies at earlier stages and monitor treatment efficacy without the invasiveness of tissue biopsies, directly propelling the adoption and development of EV-based platforms.

Key Market Challenges

A substantial challenge impeding the growth of the Global EV-Based Liquid Biopsy Market is the ongoing technical complexity associated with isolating and comprehensively characterizing extracellular vesicles (EVs) from complex biofluids. This inherent variability in isolation methods and subsequent characterization protocols often leads to significant issues with reproducibility and consistent clinical validation. The lack of standardized procedures across different laboratories and platforms directly compromises the reliability of test results, creating skepticism among clinicians and delaying the widespread adoption of EV-based diagnostic solutions.

Key Market Trends

The emergence of novel EV biomarkers is significantly shaping the global EV-based liquid biopsy market by enhancing diagnostic precision and expanding application areas. Research into disease-specific cargo within extracellular vesicles, such as proteins and nucleic acids, is uncovering new targets for early detection and disease monitoring across various pathologies. This focus on biomarker discovery drives the development of more sensitive and specific diagnostic assays. According to the International Society for Extracellular Vesicles, its MISEV2023 guidelines, published in March 2024, garnered consensus from approximately 97% of surveyed members, reflecting a widespread scientific commitment to standardizing and advancing EV research which underpins biomarker identification. This collective effort is crucial for translating promising biomarker candidates into validated clinical tools. Furthermore, a review article in *Biology (Basel)* in September 2024, highlighted the therapeutic opportunity of tumor-derived extracellular vesicles, emphasizing their capacity to harbor cancer-derived cargo reflective of their cell-of-origin and their superior stability in blood for diagnostic and prognostic insights.

Key Market Players

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc.
  • Lonza Group AG
  • Takara Bio Inc.
  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd.
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp.
  • Bio-Techne Corporation

Report Scope:

In this report, the Global EV-Based Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

EV-Based Liquid Biopsy Market , By Offering:

  • Kits & Assays
  • Services
  • Instruments

EV-Based Liquid Biopsy Market , By Workflow:

  • Sample Preparation
  • Sequencing
  • Data Analysis

EV-Based Liquid Biopsy Market , By Technology:

  • Isolation Technologies
  • Analysis Technologies

EV-Based Liquid Biopsy Market , By Sample Type:

  • Blood
  • Urine
  • Saliva
  • Others

EV-Based Liquid Biopsy Market , By End User:

  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Clinical Laboratories

EV-Based Liquid Biopsy Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global EV-Based Liquid Biopsy Market .

Available Customizations:

Global EV-Based Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global EV-Based Liquid Biopsy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offering (Kits & Assays, Services, Instruments)
    • 5.2.2. By Workflow (Sample Preparation, Sequencing, Data Analysis)
    • 5.2.3. By Technology (Isolation Technologies, Analysis Technologies)
    • 5.2.4. By Sample Type (Blood, Urine, Saliva, Others)
    • 5.2.5. By End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Clinical Laboratories)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America EV-Based Liquid Biopsy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offering
    • 6.2.2. By Workflow
    • 6.2.3. By Technology
    • 6.2.4. By Sample Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States EV-Based Liquid Biopsy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offering
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Sample Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada EV-Based Liquid Biopsy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offering
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Sample Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico EV-Based Liquid Biopsy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offering
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Sample Type
        • 6.3.3.2.5. By End User

7. Europe EV-Based Liquid Biopsy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offering
    • 7.2.2. By Workflow
    • 7.2.3. By Technology
    • 7.2.4. By Sample Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany EV-Based Liquid Biopsy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offering
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Sample Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France EV-Based Liquid Biopsy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offering
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Sample Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom EV-Based Liquid Biopsy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offering
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Sample Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy EV-Based Liquid Biopsy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offering
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Sample Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain EV-Based Liquid Biopsy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offering
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Sample Type
        • 7.3.5.2.5. By End User

8. Asia Pacific EV-Based Liquid Biopsy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offering
    • 8.2.2. By Workflow
    • 8.2.3. By Technology
    • 8.2.4. By Sample Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China EV-Based Liquid Biopsy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offering
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Sample Type
        • 8.3.1.2.5. By End User
    • 8.3.2. India EV-Based Liquid Biopsy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offering
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Sample Type
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan EV-Based Liquid Biopsy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offering
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Sample Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea EV-Based Liquid Biopsy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offering
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Sample Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia EV-Based Liquid Biopsy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offering
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Sample Type
        • 8.3.5.2.5. By End User

9. Middle East & Africa EV-Based Liquid Biopsy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offering
    • 9.2.2. By Workflow
    • 9.2.3. By Technology
    • 9.2.4. By Sample Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia EV-Based Liquid Biopsy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offering
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Sample Type
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE EV-Based Liquid Biopsy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offering
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Sample Type
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa EV-Based Liquid Biopsy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offering
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Sample Type
        • 9.3.3.2.5. By End User

10. South America EV-Based Liquid Biopsy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offering
    • 10.2.2. By Workflow
    • 10.2.3. By Technology
    • 10.2.4. By Sample Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil EV-Based Liquid Biopsy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offering
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Sample Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia EV-Based Liquid Biopsy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offering
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Sample Type
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina EV-Based Liquid Biopsy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offering
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Sample Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global EV-Based Liquid Biopsy Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Horiba Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific, Inc.
  • 15.3. Lonza Group AG
  • 15.4. Takara Bio Inc.
  • 15.5. Abcam plc
  • 15.6. Qiagen N.V.
  • 15.7. Malvern Panalytical Ltd.
  • 15.8. Revvity, Inc. (PerkinElmer, Inc)
  • 15.9. Norgen Biotek Corp.
  • 15.10. Bio-Techne Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제